GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
W

WuXi Biologics (Cayman) 2269.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

48.92

+2.73%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥25.36bn

FY2016FY2025

Net income

CN¥5.71bn

FY2016FY2025

Free cash flow

CN¥3.26bn

FY2016FY2025

Shareholders' equity

CN¥55.01bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥25.36bnCN¥21.73bnCN¥19.82bnCN¥17.77bnCN¥11.98bnCN¥6.53bnCN¥4.64bnCN¥2.95bnCN¥1.88bnCN¥1.15bn
Gross profitCN¥11.66bnCN¥8.90bnCN¥7.95bnCN¥7.83bnCN¥5.62bnCN¥2.95bnCN¥1.93bnCN¥1.18bnCN¥768.7mCN¥452.8m
Research and developmentCN¥1.00bnCN¥892.0mCN¥922.4mCN¥794.6mCN¥583.7mCN¥353.5mCN¥302.2mCN¥197.0mCN¥86.7mCN¥62.0m
Operating incomeCN¥7.73bnCN¥5.79bnCN¥5.18bnCN¥5.05bnCN¥4.69bnCN¥1.75bnCN¥1.29bnCN¥1.02bnCN¥405.7mCN¥234.5m
Net incomeCN¥5.71bnCN¥3.91bnCN¥3.96bnCN¥5.14bnCN¥3.94bnCN¥1.97bnCN¥1.18bnCN¥733.9mCN¥294.0mCN¥164.2m
Diluted earnings per share1.370.920.911.180.890.480.300.180.080.06

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥74.16bnCN¥66.31bnCN¥65.84bnCN¥57.68bnCN¥51.24bnCN¥33.71bnCN¥20.48bnCN¥10.93bnCN¥5.64bnCN¥2.31bn
Cash and short-term investmentsCN¥18.32bnCN¥12.46bnCN¥13.08bnCN¥10.14bnCN¥12.95bnCN¥9.87bnCN¥7.85bnCN¥4.75bnCN¥2.40bnCN¥196.8m
Total liabilitiesCN¥12.41bnCN¥13.38bnCN¥14.61bnCN¥15.54bnCN¥13.18bnCN¥9.38bnCN¥5.48bnCN¥1.63bnCN¥959.6mCN¥2.00bn
DebtCN¥3.61bnCN¥4.94bnCN¥4.56bnCN¥4.42bnCN¥4.30bnCN¥3.33bnCN¥2.19bn——CN¥1.13bn
Shareholders' equityCN¥55.01bnCN¥48.67bnCN¥46.94bnCN¥40.79bnCN¥37.56bnCN¥23.93bnCN¥14.88bnCN¥9.30bnCN¥4.68bnCN¥314.8m
Shares outstanding4,166m4,227m4,348m4,365m4,436m4,085m3,884m3,985m3,873m2,892m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥7.43bnCN¥6.07bnCN¥5.43bnCN¥6.45bnCN¥3.99bnCN¥2.19bnCN¥1.41bnCN¥886.3mCN¥419.3mCN¥95.3m
Capital spending−CN¥4.18bn−CN¥4.57bn−CN¥4.92bn−CN¥6.83bn−CN¥7.59bn−CN¥7.01bn−CN¥3.76bn−CN¥2.13bn−CN¥800.4m−CN¥499.1m
Free cash flowCN¥3.26bnCN¥1.50bnCN¥508.8m−CN¥380.2m−CN¥3.60bn−CN¥4.82bn−CN¥2.36bn−CN¥1.24bn−CN¥381.1m−CN¥403.8m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022
RevenueCN¥13.53bnCN¥13.78bnCN¥11.58bnCN¥11.76bnCN¥9.98bnCN¥9.94bnCN¥9.88bnCN¥9.38bn
Gross profitCN¥6.25bnCN¥6.71bnCN¥4.95bnCN¥5.01bnCN¥3.90bnCN¥3.80bnCN¥4.14bnCN¥3.85bn
Operating incomeCN¥4.28bnCN¥4.56bnCN¥3.17bnCN¥3.67bnCN¥2.12bnCN¥1.92bnCN¥2.68bnCN¥2.17bn
Net incomeCN¥2.80bnCN¥2.99bnCN¥2.72bnCN¥2.16bnCN¥1.74bnCN¥1.32bnCN¥2.64bnCN¥2.19bn
Diluted earnings per share0.670.720.650.510.410.300.610.50
Cash from operations—CN¥5.35bnCN¥2.10bnCN¥4.56bnCN¥1.51bnCN¥2.72bnCN¥2.72bnCN¥4.75bn
Capital spending—−CN¥2.10bn−CN¥2.21bn−CN¥2.40bn−CN¥2.17bn−CN¥2.46bn−CN¥2.46bn−CN¥3.71bn
Free cash flow—CN¥3.25bn−CN¥109.0mCN¥2.16bn−CN¥658.0mCN¥255.0mCN¥255.0mCN¥1.05bn
Total assetsCN¥76.05bnCN¥74.16bnCN¥70.33bnCN¥66.31bnCN¥65.29bnCN¥65.84bnCN¥60.68bnCN¥57.68bn
Cash and short-term investmentsCN¥15.17bnCN¥18.32bnCN¥14.59bnCN¥12.46bnCN¥11.09bnCN¥13.08bnCN¥10.12bnCN¥10.14bn
DebtCN¥746.4mCN¥3.61bnCN¥5.94bnCN¥5.75bnCN¥5.32bnCN¥5.31bnCN¥5.98bnCN¥5.15bn
Shareholders' equityCN¥55.93bnCN¥55.01bnCN¥52.31bnCN¥48.67bnCN¥47.31bnCN¥46.94bnCN¥43.92bnCN¥40.79bn

Financial ratios

Data as of 6 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin46.0%41.0%40.1%44.0%46.9%45.1%
Operating margin30.5%26.6%26.1%28.4%39.2%26.8%
Net margin22.5%18.0%20.0%29.0%32.9%30.1%
Return on equity10.4%8.0%8.4%12.6%10.5%8.2%
Return on assets7.7%5.9%6.0%8.9%7.7%5.8%
Free cash flow yield4.9%4.4%4.2%5.3%4.6%3.9%
Revenue growth16.7%9.6%11.6%48.4%83.3%40.9%
Earnings growth46.3%-1.3%-23.1%30.5%100.6%66.6%
Current ratio3.14x2.73x2.78x1.98x2.37x3.16x
Debt to equity0.03x0.07x0.06x0.08x0.09x0.13x
Equity ratio74.2%73.4%71.3%70.7%73.3%71.0%
Interest coverage47.65x31.56x28.08x67.44x102.89x35.15x
R&D as a share of sales3.9%4.1%4.7%4.5%4.9%5.4%
Buybacks as a share of market value1.5%2.8%0.4%1.6%-8.6%-5.2%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue12.6%31.2%44.3%
Operating income15.2%34.6%59.5%
Net income3.6%23.8%60.0%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin43.7%42.9%43.5%43.2%
Operating margin28.7%28.0%29.3%29.0%
Net margin20.4%22.1%23.9%23.6%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings20.216.728.644.791.6187.995.279.8168.8
Price to sales4.53.05.712.930.256.624.219.926.4

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 3-for-1 split · 16 Nov 2020

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.